Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemohormonal Therapy in High Risk Prostate Cancer
NCT03358563Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Complete Pathologic Response Rate at 6 months. Started Jan 2018; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03358563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358563.